-
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial
Beernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell-McGee, A., Casillas, D., Driscoll, L., Greasley, P. J., Karlsson, C., Hammarstedt, A., Sridhar, V. S., Muskiet, M. H. A., Laverman, G. D., Cherney, D. Z. I., Bjornstad, P., van Raalte, D. H. & Heerspink, H. J. L., Aug 2025, In: Diabetes, Obesity and Metabolism. 27, 8, p. 4415-4426 12 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial
van Baar, M. J. B., Muskiet, M. H. A., Scholtes, R. A., Touw, D. J., Nieuwdorp, M., Kramer, M. H. H., Joles, J. A., Cherney, D. Z. I., Bjornstad, P., Krebber, M. M. & van Raalte, D. H., Jul 2025, In: Diabetes, Obesity and Metabolism. 27, 7, p. 3943-3956 14 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
The gut–bone axis: implications of gut hormone-based therapies for bone health
Muskiet, M. H. A., Winter, E. M., Rensen, P. C. N., Appelman-Dijkstra, N. M. & de Jongh, R. T., 1 May 2025, In: The Lancet Diabetes and Endocrinology. 13, 5, p. 364-367 4 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
- All publications
